JP2018509393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509393A5 JP2018509393A5 JP2017541310A JP2017541310A JP2018509393A5 JP 2018509393 A5 JP2018509393 A5 JP 2018509393A5 JP 2017541310 A JP2017541310 A JP 2017541310A JP 2017541310 A JP2017541310 A JP 2017541310A JP 2018509393 A5 JP2018509393 A5 JP 2018509393A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- dosage form
- unit dosage
- polypeptide
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562113300P | 2015-02-06 | 2015-02-06 | |
| US62/113,300 | 2015-02-06 | ||
| PCT/US2016/016842 WO2016127097A1 (en) | 2015-02-06 | 2016-02-05 | Methods and compositions for improved cognition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509393A JP2018509393A (ja) | 2018-04-05 |
| JP2018509393A5 true JP2018509393A5 (https=) | 2019-03-22 |
| JP6794363B2 JP6794363B2 (ja) | 2020-12-02 |
Family
ID=56564770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541310A Active JP6794363B2 (ja) | 2015-02-06 | 2016-02-05 | 認知の向上のための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US10632180B2 (https=) |
| EP (2) | EP3957317A1 (https=) |
| JP (1) | JP6794363B2 (https=) |
| CN (2) | CN107405382A (https=) |
| AU (2) | AU2016215080B2 (https=) |
| CA (1) | CA2974988A1 (https=) |
| HK (1) | HK1246193A1 (https=) |
| WO (1) | WO2016127097A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107405382A (zh) | 2015-02-06 | 2017-11-28 | 加利福尼亚大学董事会 | 用于改善认知的方法和组合物 |
| WO2017085317A1 (en) * | 2015-11-19 | 2017-05-26 | Universitat Autonoma De Barcelona | Secreted splicing variant of mammal klotho as a medicament for cognition and behaviour impairments |
| JP2018184369A (ja) * | 2017-04-26 | 2018-11-22 | 株式会社明治 | 知的作業能力向上用組成物および認知能力向上用組成物 |
| WO2019140250A1 (en) * | 2018-01-12 | 2019-07-18 | New York University | SOLUBLE α-KLOTH PROTEINS, PROTEIN FRAGMENTS, AND USES THEREOF |
| US20210106579A1 (en) * | 2018-05-17 | 2021-04-15 | Neuralstem, Inc. | Amelioration of cognitive and motor deficits associated with alzheimer's |
| WO2020106997A1 (en) * | 2018-11-21 | 2020-05-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and materials for reducing age-related striated muscle and cognitive decline |
| EP4103223A4 (en) | 2020-02-12 | 2024-05-29 | The Regents of the University of California | PLATELET FACTORS AND COGNITIVE IMPROVEMENT |
| US20230123357A1 (en) * | 2020-03-04 | 2023-04-20 | The Regents Of The University Of California | Use of downstream factors in the klotho pathway to assess klotho activity |
| WO2024084400A2 (en) * | 2022-10-17 | 2024-04-25 | Bio Immunitas Ltd. | Alpha 2 macroglobulin, soluble klotho and methods of use thereof |
| WO2024092238A1 (en) * | 2022-10-28 | 2024-05-02 | Unity Biotechnology, Inc. | Klotho polypeptide or polynucleotide for improving cognition |
| EP4434534A1 (en) | 2023-03-22 | 2024-09-25 | ADvantage Therapeutics, Inc. | Klotho mrna |
| CN117797249A (zh) * | 2023-11-14 | 2024-04-02 | 苏州祥沁医疗科技有限公司 | 基于mRNA的抗衰老抗老年痴呆预防及治疗疫苗 |
| WO2025168038A1 (en) * | 2024-02-07 | 2025-08-14 | Kunming Institute Of Zoology, Chinese Academy Of Sciences | Methods and compositions for ameliorating impairment of regenerative and cognitive function |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452720A (en) | 1980-06-04 | 1984-06-05 | Teijin Limited | Fluorescent composition having the ability to change wavelengths of light, shaped article of said composition as a light wavelength converting element and device for converting optical energy to electrical energy using said element |
| US4732863A (en) | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
| US5330900A (en) | 1987-12-31 | 1994-07-19 | Tropix, Inc. | Chemiluminescent 3-(substituted adamant-2'-ylidene) 1,2-dioxetanes |
| US5227487A (en) | 1990-04-16 | 1993-07-13 | Molecular Probes, Inc. | Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes |
| ES2281112T3 (es) | 1996-12-26 | 2007-09-16 | Kyowa Hakko Kogyo Co., Ltd. | Proteina que presenta una actividad de supresion del envejecimiento. |
| US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| US20050037954A1 (en) * | 2001-03-23 | 2005-02-17 | Masaki Hirashima | Novel agents for ameliorating motor disorder |
| US20040101874A1 (en) | 2002-04-12 | 2004-05-27 | Mitokor Inc. | Targets for therapeutic intervention identified in the mitochondrial proteome |
| US20040001859A1 (en) | 2002-06-28 | 2004-01-01 | Cheung Ling Yuk | Anti-aging dietary supplements |
| JP2006240990A (ja) | 2003-05-15 | 2006-09-14 | Kirin Brewery Co Ltd | ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途 |
| EP2152295B1 (en) | 2007-05-08 | 2018-04-18 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Klotho protein and related compounds for the treatment of cancer |
| US8420088B2 (en) * | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| CN101711779B (zh) * | 2008-10-08 | 2012-12-05 | 中南大学 | 垫状卷柏提取物在制备抗阿尔茨海默病药物中的用途 |
| CA2783555A1 (en) | 2009-12-16 | 2011-07-14 | Eli Lilly And Company | Therapeutic uses of soluble alpha-klotho |
| US20110195077A1 (en) * | 2010-01-29 | 2011-08-11 | Novartis Ag | Methods and compositions using fgf23 fusion ppolypeptides |
| JP2012184184A (ja) * | 2011-03-04 | 2012-09-27 | Nara Medical Univ | 抗老化作用を有するヤドリギ抽出物 |
| AU2015356643B2 (en) | 2014-12-04 | 2019-01-24 | Novartis Ag | Methods and compositions using Klotho variant polypeptides |
| CN107405382A (zh) | 2015-02-06 | 2017-11-28 | 加利福尼亚大学董事会 | 用于改善认知的方法和组合物 |
| WO2017085317A1 (en) | 2015-11-19 | 2017-05-26 | Universitat Autonoma De Barcelona | Secreted splicing variant of mammal klotho as a medicament for cognition and behaviour impairments |
-
2016
- 2016-02-05 CN CN201680019604.8A patent/CN107405382A/zh active Pending
- 2016-02-05 AU AU2016215080A patent/AU2016215080B2/en active Active
- 2016-02-05 JP JP2017541310A patent/JP6794363B2/ja active Active
- 2016-02-05 WO PCT/US2016/016842 patent/WO2016127097A1/en not_active Ceased
- 2016-02-05 HK HK18105784.9A patent/HK1246193A1/zh unknown
- 2016-02-05 EP EP21187176.9A patent/EP3957317A1/en not_active Withdrawn
- 2016-02-05 US US15/548,306 patent/US10632180B2/en active Active
- 2016-02-05 CN CN202511208412.9A patent/CN121102455A/zh active Pending
- 2016-02-05 CA CA2974988A patent/CA2974988A1/en active Pending
- 2016-02-05 EP EP16747364.4A patent/EP3253403B1/en active Active
-
2018
- 2018-05-24 US US15/988,216 patent/US10300117B2/en active Active
-
2020
- 2020-01-23 US US16/751,108 patent/US10864256B2/en active Active
- 2020-11-11 US US17/095,673 patent/US11738070B2/en active Active
- 2020-12-02 AU AU2020281046A patent/AU2020281046B2/en active Active
-
2023
- 2023-06-28 US US18/215,276 patent/US12239694B2/en active Active
-
2025
- 2025-01-17 US US19/028,837 patent/US20250161418A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509393A5 (https=) | ||
| Raghav et al. | Nose-to-brain drug delivery: Challenges and progress towards brain targeting in the treatment of neurological disorders | |
| US9757391B2 (en) | Neuroactive steroids and their use to facilitate neuroprotection | |
| JP2021518365A5 (https=) | ||
| JP2018520189A5 (https=) | ||
| WO2015037248A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| US9809823B2 (en) | DNA aptamers for promoting remyelination | |
| TW200918051A (en) | Treatment of progressive neurodegenerative disease with ibudilast | |
| EP4306167B1 (en) | Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases | |
| US9486540B2 (en) | Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders | |
| KR20090118078A (ko) | 척수 손상 치료제 | |
| SG178942A1 (en) | Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same | |
| WO2023063242A1 (ja) | ＩＦＮ－γへ選択的に結合するオリゴヌクレオチドを含有する自己免疫性疾患治療薬およびそのオリゴヌクレオチド | |
| WO2007139433A8 (en) | Peptide substance normalizing the metabolism in osseous and cartilaginous tissues, pharmaceutical composition on its base and the method of its application | |
| US20220257582A1 (en) | Treatment for synucleinopathies | |
| JP2022511673A5 (https=) | ||
| EP2473174A2 (en) | Ganglioside transmucosal formulations | |
| Kshirsagar et al. | Use of ketamine in refractory bronchospasm-a study of 20 cases | |
| JP2013509422A5 (https=) | ||
| EP3697808B1 (en) | Neuroprotective peptide | |
| JIANG et al. | Research progress on the clinical application of esketamine | |
| RU2013139704A (ru) | Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера | |
| WO2025199248A1 (en) | Formulations and methods for treating dementia and alzheimer's disease | |
| WO2024108269A1 (en) | Neuroprotective compositions and methods | |
| WO2025052180A2 (en) | Lipids and lipid nanoparticles |